Antibiotic Pipeline Revival: FDA Approves Cubist Pharmaceuticals' SIVEXTRO™ For MRSA, Other Serious Skin Infections

June 20, 2014 10:38 PM

20 0

Antibiotic Pipeline Revival: FDA Approves Cubist Pharmaceuticals' SIVEXTRO™ For MRSA, Other Serious Skin Infections

Late this afternoon, the U.S. Food and Drug Administration approved Cubist Pharmaceuticals’ tedizolid phosphate (SIVEXTRO™) for the treatment of acute adult bacterial skin and skin structure infections, or ABSSSIs.

The specific approved targets of Sivextro are infections caused by Gram-positive bacteria that include: Staphylococcus aureus (including methicillin-resistant [MRSA] and methicillin-susceptible [MSSA] isolates), Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus anginosus group (includi...

Read more

To category page

Loading...